The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Recruitment feasibility as assessed by the number of caregivers who consent/number of caregivers who meet eligibility criteria.
Timeframe: 30 months
Retention feasibility as assessed by the number of caregivers completing primary endpoint measures/number of caregivers consented.
Timeframe: 30 months
Adherence feasibility as assessed by the number of caregivers completing all PEARL sessions/number of caregivers consented.
Timeframe: 30 months
Acceptability of PEARL therapy from the perspective of the caregivers of patients with advanced cancer obtained through qualitative interviews.
Timeframe: 30 months
Safety of PEARL therapy.
Timeframe: 30 months